Abdominal Pain in Irritable Bowel Syndrome (IBS)


Recurrent abdominal pain or discomfortb at least 3 days/month in the last 3 months associated with two or more of the following:

1. Improvement with defecation

2. Onset associated with a change in frequency of stool

3. Onset associated with a change in form (appearance) of stool


aCriterion fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

b“Discomfort” means an uncomfortable sensation not described as pain



1.

IBS is a global problem that affects individuals all over the world [3]. The reported worldwide prevalence rates for IBS range from 5 % to 20 %.

 

2.

In most countries IBS affects women (60–70 %) more than men [4, 5]. The East is unique in that there are reports from China, Taiwan, and Singapore of a similar prevalence between males and females [6, 7]. There are conflicting reports from India with community-based surveys reporting higher prevalence of IBS among females in the general population and hospital-based surveys reporting higher proportion of males among patients in gastroenterology clinics [8, 9]. The latter observation might reflect cultural aspects of healthcare-seeking behaviors in Indian society.

 

3.

Although IBS can appear at any age, it is more common in young and middle-aged patients and tends to be less common in the elderly [10, 11].

 

4.

Socioeconomic status may play a role in the epidemiology of IBS, which has been reported in some countries to be more prevalent in lower socioeconomic classes [4, 12, 13], although the data on this factor are not consistent.

 


As a prevalent chronic disorder, IBS places a major economic burden on health care. A meta-analysis of 18 studies from the USA and the UK estimated the annual direct cost of an IBS patient (drugs, procedures, and doctor visits) at $348–8,750 and the annual indirect costs (loss of work days and deceased productivity) at $355–3,344 [14, 15]. Another US study estimated the overall annual direct cost of IBS to be $228 million in doctor visits and $80 million in drugs [15].



Diagnosis


There is no specific diagnostic finding or biomarker for IBS, so the diagnosis is based on patients’ reports of their symptoms. In the past, IBS was considered a diagnosis of exclusion, but inherent to this approach is an exhaustive diagnostic work-up that involves unpleasant and potentially risky tests for the patient and is not cost effective. Thus, a symptom-based diagnostic system, known as the Rome criteria, was developed. The main concept introduced by the Rome criteria is that the diagnostic process of a functional disorder should be based on two components. The first is the presence of a typical cluster of symptoms and the second is the absence of “red flags” including initial presentation of symptoms at an age over 50, unexplained weight loss, fever, nocturnal symptoms, blood in the stool, a family history of gastrointestinal malignancy or disease (e.g., celiac or inflammatory bowel disease), or an abnormal finding on physical examination. Basic laboratory tests, such as a complete blood count and celiac serology, are usually enough to complete the diagnostic process and establish a firm diagnosis. Patients who fulfill the criteria and do not have red flags need a minimal diagnostic work-up after which the diagnosis of IBS can be made with confidence [16, 17].

The latest update of the Rome diagnostic criteria for IBS is Rome III, in which the diagnosis of IBS requires the presence of abdominal pain or discomfort for at least 10 % of the time over the previous three months with symptom onset at least six months earlier [18]. Additionally, pain should be relieved by defecation and associated with a change in the frequency of bowel movements or a change in the form of the stool. Accompanying symptoms, although not essential for the diagnosis, are a feeling of incomplete evacuation, abnormal stool frequency (less than three times a week or more than three times a day) or consistency, straining at defecation, urgency, mucus discharge, and bloating. IBS can be further divided into three main subgroups according to bowel habit as constipation predominant (IBS-C), diarrhea predominant (IBS-D), and those exhibiting an alternating bowel pattern [19]. Patients may switch from one subclass to another during the course of their illness. It has been demonstrated repeatedly that the use of positive symptom-based diagnostic criteria in conjunction with the use of red flags to guide further investigation in selected cases is a reliable and cost-effective approach. After establishing the diagnosis of IBS, based on the Rome criteria, it is rarely necessary to change the diagnosis [2022].


The Pathophysiology of Pain in IBS


Abdominal pain is a hallmark of IBS and is essential for its diagnosis. In IBS, as in many other chronic pain syndromes, pain is a complex experience resulting from the interplay between peripheral (visceral) stimulation (enteric nervous system) and central modulation (central nervous system [CNS]).

Afferent stimulation from the colon is transmitted to second-order neurons in the spinal cord and then ascends to the brain through the spinothalamic, spinoreticular, and spinomesencephalic tracts. These tracts connect to the somatosensory cortex responsible for registration and localization of painful visceral and somatic stimuli. They also connect to structures in the limbic system that are involved in the reflexive, affective, and motivational responses to pain [23]. The afferent pathways project to the perigenual anterior cingulate cortex (pACC), which is involved in affective modification, and to the midcingulate cortex (MCC), which is involved in the behavioral response.

The amplification of afferent visceral stimulation can result from increased excitability of peripheral receptors or impaired spinal and/or central pain regulatory systems. Increased excitability can produce the two related phenomena of hyperalgesia (increased pain response to painful stimuli) and allodynia (increased pain response to nonpainful stimuli) [24]. Thus, afferent visceral stimulation can be experienced as painful not only as a result of peripheral intensity but also as a result of central processing that may be modulated by psychosocial factors such as anxiety, depression, poor social support, and impaired coping skills [25]. As the severity of pain increases central processing plays an increasingly important role compared to peripheral input. Once a pattern of central sensitization has taken hold, patients may even experience severe pain without ongoing peripheral nociceptive stimulation [26, 27]. This is the extreme end of the IBS severity spectrum.

While we do not have full knowledge of all the causes of excessive peripheral stimulation, there is good evidence that eating, infection, inflammation, physical injury, hormones (e.g., menses), or colonic motility may play a role.

Up to 15 % of IBS patients attribute the beginning of their symptoms to an acute episode of gastrointestinal infection. A meta-analysis of eight papers including almost 600,000 patients over a follow-up up to one year found that the odds ratio for developing IBS after such an episode is seven [28]. IBS that follows acute intestinal infection has been shown to be associated with a persistent or chronic state of inflammation that cannot be identified by routine clinical tests and procedures [29, 30].

Risk factors for postinfectious IBS are related to not only to the severity of the acute infectious episode (fever, bloody stools, and need for hospitalization) but also to patient characteristics such as female gender, stress, anxiety, and depression [31]. This is a good example of how excessive afferent stimulation, induced in this case by a microinflammatory state, can develop into a chronic condition such as IBS-D after central sensitization occurs in a susceptible person with psychological comorbidity.

Peripheral stimulation and its interplay with central amplification are also reflected in the development of chronic abdominal pain following abdominal or pelvic surgery. IBS patients reported up to twice the number of appendectomies and hysterectomies and up to three times the number of cholecystectomies compared with those without IBS [32]. Surgery may cause visceral afferent sensitization that eventually results in allodynia and chronic pain even in the presence of normal gut function.

This contention is supported by a study that evaluated the development of abdominal pain after elective gynecologic surgery for nonpainful indications [32]. Patients with no prior history of chronic abdominal pain undergoing gynecological surgery for nonpainful indications were followed for the development of de novo abdominal pain following surgery. They were compared with a control group comprised of nonsurgical patients who came to a gynecologic clinic for nonpain-related reasons. At one-year follow-up significantly more patients in the surgery group complained of chronic abdominal pain (15.3 %) than in the control group (3.6 %, p = 0.003). There was no association between any surgery-related variables and the subsequent development of chronic abdominal pain. The only predictors of chronic abdominal pain at one-year follow-up were associated with the patients’ preoperative psychological profile. Patients anticipating difficulty with surgery or recovery from it and those with lower scores on the Sense of Coherence questionnaire (an index of coping skills) were more likely to develop chronic postoperative abdominal pain. In these cases, the interplay of peripheral visceral stimulus together with central sensitization related to psychosocial variables affected the de novo development of chronic abdominal pain.

Studies using functional MRI and PET CT have demonstrated that the ACC, which is responsible for descending pain inhibition, is less active in IBS patients. This phenomenon is also found in other chronic pain syndromes such as fibromyalgia [3335]. In contrast, the MCC, which is associated with unpleasantness and fear, is overactive. Therefore, in IBS patients the normal adaptive inhibitory response to painful visceral stimuli is diminished and replaced by a maladaptive, presumably even aggravating, response [33, 34, 36]. The factors that ultimately lead to this shift into a maladaptive pattern are psychosocial in nature. This connection was elegantly demonstrated in the case report of a patient with a severe functional gastrointestinal pain syndrome and a history of abuse [37]. Her baseline brain scan demonstrated marked activation of the MCC and the somatosensory cortex. Following successful treatment with antidepressants and psychotherapy a repeated scan demonstrated diminished MCC activity and increased insular activation. Thus, maladaptive brain responses are reversible and so is the patient’s clinical situation.


Treatment of Abdominal Pain in IBS


As in other fields of medicine, in particular in patients with chronic painful conditions, the healing process for IBS patients begins when the patient enters the doctor’s office before any medicine has been prescribed. It is of the outmost importance to establish a good doctor–patient relationship in order to succeed in the therapeutic process [38, 39]. Some of the essentials of a salutary doctor–patient relationship are discussed below:

1.

Allow enough time especially for the first meeting. The patient should feel that the doctor is listening to and him/her and that their symptoms are considered legitimate and are being taken seriously.

 

2.

Take a full detailed history and perform a physical examination: These basic measures of good clinical practice help to foster the doctor–patient relationship.

 

3.

It is very helpful to remember four key questions that patients should be asked:

a.

What brings you here at this time? IBS is a chronic condition and many patients have their symptoms for years before consulting a specialist. Consultation is often driven by a specific anxiety or a stressful situation that should be addressed.

 

b.

What do you think is the cause of your symptoms? Many IBS patients attribute their symptoms to undiagnosed cancer, infection, inflammatory bowel disease, or food allergy.

 

c.

What are your concerns or worries? It is important to understand the patient’s agenda and to address their primary concerns such as “What exactly do I have?” or “Do I have cancer,” or alternatively related to the symptoms like “I can’t deal with this pain anymore.”

 

d.

What are your expectations from me? Some patients have the unrealistic expectation of a “quick fix” for their situation that can lead to mutual frustration and treatment failure [40]. It should be emphasized that treating IBS is a process rather than an isolated consultation and that the goal of treatment is to reduce their suffering and to improve their quality of life rather than to “cure” them.

 

 

Many IBS patients have never received a comprehensive explanation about the nature of their problem. This may be the basis for the unwarranted fears (“I might have cancer”) and feelings of frustration (“why can’t they figure out what I have”). A detailed explanation about the nature of functional disorders and their natural history is very important to deal with these issues.

Treating IBS patients is an ongoing process that takes time. Throughout this process patients are likely to encounter difficulties, setbacks, and frustration. Patients should not feel that they are left alone to deal with their setbacks. Scheduling a follow-up phone call, for example, is a simple measure that is often sufficient to allay patients’ new concerns [41]. Physicians should inquire about comorbid gastrointestinal and nongastrointestinal functional disorders. IBS patients have a high prevalence of other functional disorders [42], leading some patients to feel that they are very ill. By providing patients with a unifying paradigm that connects different, apparently unrelated, symptoms to one disorder (i.e., central sensitization), we can alleviate much of their fears and concerns.

For some patients with mild symptoms, these steps may be enough to alleviate fears and concerns regarding their symptoms. These patients often continue to cope successfully with their symptoms and need no further treatment. However, the majority of patients will require more specific treatment.

The treatment options for IBS can be divided into pharmacological and nonpharmacological treatment modalities (Fig. 6.1).

A272336_1_En_6_Fig1_HTML.gif


Fig. 6.1
Treatment options for IBS in addition to a therapeutic doctor–patient therapeutic partnership. Although there is not cure for IBS, a large number of treatment options are available to reduce suffering and improve quality of life. Doctors need not feel “empty handed” when coming to treat these patients


Medical Treatment


Medical treatment of IBS includes peripherally acting agents and centrally acting agents.


Peripherally Acting Agents


These drugs act on the gut itself and are targeted against specific IBS symptoms such altered bowel movements, bloating, and cramps. Because they are not key agents in IBS pain management only some of them are discussed in detail and the rest is mentioned briefly. Table 6.2 summarizes the main facts about the different peripheral agents. Serotonin (5HT) is an important neurotransmitter that coordinates gut function and has played a key role in research and drug development. It is secreted from enterochromaffin cells in the mucosa and is involved in almost every aspect of gut function including motility, sensation, and secretion. Alosetron is a 5HT3 receptor antagonist that was shown to improve global IBS symptoms and pain in women with IBS-D. A meta-analysis comparing 12 randomized controlled trials that evaluated the efficacy of alosetron compared to placebo found an odds ratio of 1.85 for improvement in the alosetron group [43]. Unfortunately, after initial FDA approval, safety issues and in particular ischemic colitis and severe constipation led to its withdrawal from the market. It was reintroduced in 2002 under a restricted access program. Under this program, alosetron can be prescribed (under some restrictions) to women with severe IBS-D who have failed to respond to traditional medical therapies.


Table 6.2
Peripheral agents used most commonly in the treatment of IBS. Peripheral agents, although not primarily directed against pain, have an important role in IBS treatment. In mild IBS cases, they might suffice but in more severe IBS cases and, where pain is a cardinal symptom, central agents are preferred
















































Class

Drug

Mechanism of action

Comments

• Antispasmodics

• Pinaverium

• Direct visceral smooth muscle relaxants

• Modest effect on IBS spastic pain

• Mebeverin

• Colpermin (peppermint oil)

• Anticholinergic/antimuscarinic

• Otilinium bromide, hyoscine, and colpermin; best evidence for effectiveness

• Hyoscamine dicyclomine

• Serotonergic and other agents

• Alosetron

• 5HT3 receptor antagonist

• Available only through a restricted access program; increased incidence of ischemic colitis

• Tegaserode

• Withdrawn from the US market; an increased incidence of cardiovascular adverse events

• 5HT4 receptor agonist
 
• Linaclotide

• Guanylate cyclase-C agonist

• Recently approved in Europe and the US for IBS-C

• Lubiprostone

• Chloride channel activator

• In phase 3 studies, lubiprostone was almost twice as effective for IBS symptoms as placebo

Lubiprostone is a chloride channel activator that has been approved by the FDA for chronic constipation and IBC-C. In phase 3 studies, patients receiving lubiprostone were almost twice as likely to gain relief from overall IBS symptoms compared to patients who received placebo [44]. The main side effect of lubiprostone, nausea, is reported in 8 % of IBS-C patients who receive 8 mcg twice daily.


Centrally Acting Agents


Centrally acting agents should be the cornerstone of treatment in moderate-to-severe cases of IBS [45]. The main classes of drugs that are being used are the selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Other drugs, such as Mirtazapine, Buspiron, and the atypical antipsychotic Quetiapine, can also be used. These drugs were developed for the treatment of anxiety and depression, but can and should be used in IBS as discussed below. The different drugs and dosages are summarized in Table 6.3.


Table 6.3
Common interventions used in IBS. For optimal results these interventions can be used in combination (“augmentation” therapy). The use of more than one drug at a low dose can augment the therapeutic response and minimize the side effects
























Drug

Drug (daily dose range [mg])

Comments

TCA

• Desipramine (25–150)

• Begin with low dose and titrate by response

• Nortriptyline (25–150)

• Amitriptyline (25–150)

• Allow 4–8 weeks for maximal response

SSRIs

Only gold members can continue reading. Log In or Register to continue

Oct 16, 2016 | Posted by in PAIN MEDICINE | Comments Off on Abdominal Pain in Irritable Bowel Syndrome (IBS)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access